NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
Clinical Trials
11 trialsNCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03463408 2025-08-11
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
University of Rochester
Phase EARLY_PHASE1 Active not recruiting
NCT03162731 2025-04-29
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT05498792 2025-04-04
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT02113657 2024-05-24
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03526185 2022-07-25
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
Yale University
Phase EARLY_PHASE1 Terminated
NCT00972933 2017-12-07
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT01730157 2016-03-10
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated